The utility of performing the initial lumbar puncture on day 8 in remission induction therapy for childhood acute lymphoblastic leukemia: TCCSG L99-15 study

Pediatric Blood and Cancer

Volumn 58, Issue 1, 2012, Pages 23-30

  Hasegawa, Daisuke ^a   Manabe, Atsushi ^a   Ohara, Akira ^b   Kikuchi, Akira ^c   Koh, Katsuyoshi ^d   Kiyokawa, Nobutaka ^e   Fukushima, Takashi ^f   Ishida, Yasushi ^a   Saito, Tomohiro ^g   Hanada, Ryoji ^d   Tsuchida, Masahiro ^h  

^a ST LUKE'S INTERNATIONAL HOSPITAL   (Japan)

^b TOHO UNIVERSITY   (Japan)

^c TEIKYO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^d SAITAMA CHILDREN'S MEDICAL CENTER   (Japan)

^e NATIONAL RESEARCH INSTITUTE FOR CHILD HEALTH AND DEVELOPMENT   (Japan)

^f UNIVERSITY OF TSUKUBA   (Japan)

^g Health Center   (Japan)

^h Ibaraki Children's Hospital   (Japan)

Author keywords

Acute lymphoblastic leukemia (ALL); Central nervous system (CNS) relapse; Chemotherapy; Chemotherapy neurotoxicities

Indexed keywords

CYTARABINE; HYDROCORTISONE; METHOTREXATE; PREDNISOLONE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ARTICLE; CANCER RADIOTHERAPY; CANCER RELAPSE; CANCER SURVIVAL; CENTRAL NERVOUS SYSTEM; CEREBROSPINAL FLUID ANALYSIS; CHILD; CHILDHOOD CANCER; CONTROLLED STUDY; CRANIAL NERVE PARALYSIS; CYTOGENETICS; EVENT FREE SURVIVAL; FEMALE; FOLLOW UP; HUMAN; HUMAN CELL; LEUKEMIA REMISSION; LEUKOCYTE COUNT; LUMBAR PUNCTURE; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; RADIATION DOSE; THROMBOCYTE TRANSFUSION; TREATMENT DURATION; TREATMENT OUTCOME;

ADOLESCENT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CASE-CONTROL STUDIES; CENTRAL NERVOUS SYSTEM NEOPLASMS; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; CYTARABINE; FEMALE; HUMANS; INFANT; INJECTIONS, SPINAL; MALE; METHOTREXATE; NEOPLASM RECURRENCE, LOCAL; NETHERLANDS; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PREDNISOLONE; PROSPECTIVE STUDIES; REMISSION INDUCTION; SPINAL PUNCTURE; SURVIVAL RATE; TIME FACTORS; TREATMENT OUTCOME;

EID: 81155123173     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.22965     Document Type: Article

References (28)

1. Möricke A, Reiter A, Zimmermann M, et al. Risk-adjusted therapy of acute lymphoblastic leukemia can decrease treatment burden and improve survival: Treatment results of 2169 unselected pediatric and adolescent patients enrolled in the trial ALL-BFM 95. Blood 2008;111:4477-4489.
2. Pui CH, Campana D, Pei D, et al. Treating childhood acute lymphoblastic leukemia without cranial irradiation. N Engl J Med 2009;360:2730-2741.
3. Pui CH, Robison LL, Look AT. Acute lymphoblastic leukaemia. Lancet 2008;371:1030-1043.
4. Pui CH, Relling MV, Downing JR. Acute lymphoblastic leukemia. N Engl J Med 2004;350:1535-1548.
5. Hijiya N, Hudson MM, Lensing S, et al. Cumulative incidence of secondary neoplasms as a first event after childhood acute lymphoblastic leukemia. JAMA 2007;297:1207-1215.
6. Kikuchi A, Maeda M, Hanada R, et al. Moyamoya syndrome following childhood acute lymphoblastic leukemia. Pediatr Blood Cancer 2007;48:268-272.
7. Pui CH, Howard SC. Current management and challenges of malignant disease in the CNS in paediatric leukaemia. Lancet Oncol 2008;9:257-268.
8. Mahmoud HH, Rivera GK, Hancock ML, et al. Low leukocyte counts with blast cells in cerebrospinal fluid of children with newly diagnosed acute lymphoblastic leukemia. N Engl J Med 1993;329:314-319.
9. Gajjar A, Harrison PL, Sandlund JT, et al. Traumatic lumbar puncture at diagnosis adversely affects outcome in childhood acute lymphoblastic leukemia. Blood 2000;96:3381-3384.
10. Bürger B, Zimmermann M, Mann G, et al. Diagnostic cerebrospinal fluid examination in children with acute lymphoblastic leukemia: Significance of low leukocyte counts with blasts or traumatic lumbar puncture. J Clin Oncol 2003;21:184-188.
11. te Loo DM, Kamps WA, van der Does-van den Berg A, et al. Prognostic significance of blasts in the cerebrospinal fluid without pleiocytosis or a traumatic lumbar puncture in children with acute lymphoblastic leukemia: Experience of the Dutch Childhood Oncology Group. J Clin Oncol 2006;24:2332-2336.
12. Manabe A, Tsuchida M, Hanada R, et al. Delay of the diagnostic lumbar puncture and intrathecal chemotherapy in children with acute lymphoblastic leukemia who undergo routine corticosteroid testing: Tokyo Children's Cancer Study Group studyL89-12. J Clin Oncol 2001;19:3182-3187.
13. Pui CH. Toward optimal central nervous system-directed treatment in childhood acute lymphoblastic leukemia. J Clin Oncol 2003;21:179-181.
14. Toyoda Y, Manabe A, Tsuchida M, et al. Six months of maintenance chemotherapy after intensified treatment for acute lymphoblastic leukemia of childhood. J Clin Oncol 2000;18:1508-1516.
15. Manabe A, Ohara A, Hasegawa D, et al. Significance of the complete clearance of peripheral blasts after 7 days of prednisolone treatment in children with acute lymphoblastic leukemia: The Tokyo Children's Cancer Study Group Study L99-15. Haematologica 2008;93:1155-1160.
16. Tsuchida M, Ikuta K, Hanada R, et al. Long-term follow-up of childhood acute lymphoblastic leukemia in Tokyo Children's Cancer Study Group 1981-1995. Leukemia 2000;14:2295-2306.
17. Pui CH, Mahmoud HH, Rivera GK, et al. Early intensification of intrathecal chemotherapy virtually eliminates central nervous system relapse in children with acute lymphoblastic leukemia. Blood 1998;92:411-415.
18. Tsuchida M, Ohara A, Manabe A, et al. Long-term results of Tokyo Children's Cancer Study Group trials for childhood acute lymphoblastic leukemia, 1984-1999. Leukemia 2010;24:383-396.
19. Howard SC, Gajjar AJ, Cheng C, et al. Risk factors for traumatic and bloody lumbar puncture in children with acute lymphoblastic leukemia. JAMA 2002;288:2001-2007.
20. Balis FM, Lester CM, Chrousos GP, et al. Differences in cerebrospinal fluid penetration of corticosteroids: Possible relationship to the prevention of meningeal leukemia. J Clin Oncol 1987;5:202-207.
21. Mahoney DH, Jr., Shuster JJ, Nitschke R, et al. Acute neurotoxicity in children with B-precursor acute lymphoid leukemia: An association with intermediate-dose intravenous methotrexate and intrathecal triple therapy - a Pediatric Oncology Group study. J Clin Oncol 1998;16:1712-1722.
22. Brugnoletti F, Morris EB, Laningham FH, et al. Recurrent intrathecal methotrexate induced neurotoxicity in an adolescent with acute lymphoblastic leukemia: Serial clinical and radiologic findings. Pediatr Blood Cancer 2009;52:293-295.
23. Moghrabi A, Levy DE, Asselin B, et al. Results of the Dana-Farber Cancer Institute ALL Consortium Protocol 95-01 for children with acute lymphoblastic leukemia. Blood 2007;109:896-904.
24. Bostrom BC, Sensel MR, Sather HN, et al. Dexamethasone versus prednisone and daily oral versus weekly intravenous mercaptopurine for patients with standard-risk acute lymphoblastic leukemia: A report from the Children's Cancer Group. Blood 2003;101:3809-3817.
25. Mitchell CD, Richards SM, Kinsey SE, et al. Benefit of dexamethasone compared with prednisolone for childhood acute lymphoblastic leukaemia: Results of the UK Medical Research Council ALL97 randomized trial. Br J Haematol 2005;129:734-745.
26. Igarashi S, Manabe A, Ohara A, et al. No advantage of dexamethasone over prednisolone for the outcome of standard- and intermediate-risk childhood acute lymphoblastic leukemia in the Tokyo Children's Cancer Study Group L95-14 protocol. J Clin Oncol 2005;23:6489-6498.
27. Thyss A, Suciu S, Bertrand Y, et al. Systemic effect of intrathecal methotrexate during the initial phase of treatment of childhood acute lymphoblastic leukemia. The European Organization for Research and Treatment of Cancer Children's Leukemia Cooperative Group. J Clin Oncol 1997;15:1824-1830.
28. Flohr T, Schrauder A, Cazzaniga G, et al. Minimal residual disease-directed risk stratification using real-time quantitative PCR analysis of immunoglobulin and T-cell receptor gene rearrangements in the international multicenter trial AIEOP-BFM ALL 2000 for childhood acute lymphoblastic leukemia. Leukemia 2008;22:771-7782.